Q-omics provides the consensus-scored RNF181 profile across patient tissues and cancer cell-line models. RNF181 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RNF181 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, RNF181 RNA expression shows 19,854 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KIRC, and THYM as cancer lineages where RNF181 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF181 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF181 survival associations across molecular data types. RNF181 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF181 RNA expression–survival associations across cancer types. High RNF181 expression shows unfavorable associations in HNSC, ACC, KIRP, UCS and KICH, but favorable associations in LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RNF181 RNA expression.
This table summarizes RNF181 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RNF181. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF181 shows lower tumor expression in KICH and higher tumor expression in KIRC, BLCA, HNSC, LIHC and COAD. The KIRC box plot shows higher RNF181 RNA expression in tumor versus normal tissue (log2 FC = +1.043, t-test p < 0.001).
This table shows molecular features associated with RNF181 in patient tissues and cancer cell lines. In patient samples, RNF181 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF181 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BONE.
